GSK plc 6-K, filed May 26, 2020
GSK plc (GSK)
6-K
2020-05-26
For: 2020-05-26
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on May 26, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an ris.
Date: 26 May
2020
|
Name
of applicant:
|
GlaxoSmithKline
plc
|
|||
|
Name of
scheme:
|
GlaxoSmithKline
plc 2009 Deferred Annual Bonus Plan
|
|||
|
Period
of return:
|
From:
|
1
November 2019
|
To:
|
30
April 2020
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
153,724
|
|||
|
Plus: The amount by which the block scheme(s) has
been increased since the date of the last return (if any increase
has been applied for):
|
370,000
|
|||
|
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G):
|
388,348
|
|||
|
Equals: Balance under scheme(s) not yet
issued/allotted at end of period:
|
135,376
|
|||
|
Name of
contact:
|
Victoria
Whyte
|
|
Telephone
number of contact:
|
020
8047 5000
|
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an ris.
Date: 26 May
2020
|
Name
of applicant:
|
GlaxoSmithKline
plc
|
|||
|
Name of
scheme:
|
GlaxoSmithKline
2009 Share Option Plan - Ordinary Shares
|
|||
|
Period
of return:
|
From:
|
1
November 2019
|
To:
|
30
April 2020
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
835,095
|
|||
|
Plus: The amount by which the block scheme(s) has
been increased since the date of the last return (if any increase
has been applied for):
|
0
|
|||
|
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G):
|
581,004
|
|||
|
Equals: Balance under scheme(s) not yet
issued/allotted at end of period:
|
254,091
|
|||
|
Name of
contact:
|
Victoria
Whyte
|
|
Telephone
number of contact:
|
020
8047 5000
|
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an ris.
Date: 26 May
2020
|
Name
of applicant:
|
GlaxoSmithKline
plc
|
|||
|
Name of
scheme:
|
GlaxoSmithKline
2009 Share Option Plan - ADS
|
|||
|
Period
of return:
|
From:
|
1
November 2019
|
To:
|
30
April 2020
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
5,391,416
|
|||
|
Plus: The amount by which the block scheme(s) has
been increased since the date of the last return (if any increase
has been applied for):
|
0
|
|||
|
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G):
|
698,736
|
|||
|
Equals: Balance under scheme(s) not yet
issued/allotted at end of period:
|
4,692,680
|
|||
|
Name of
contact:
|
Victoria
Whyte
|
|
Telephone
number of contact:
|
020
8047 5000
|
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must
be typed or printed electronically and provided to
an ris.
Date: 26 May
2020
|
Name
of applicant:
|
GlaxoSmithKline
plc
|
|||
|
Name of
scheme:
|
GlaxoSmithKline
plc Share Save Plan 2012
|
|||
|
Period
of return:
|
From:
|
1
November 2019
|
To:
|
30
April 2020
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
2,145,812
|
|||
|
Plus: The amount by which the block scheme(s) has
been increased since the date of the last return (if any increase
has been applied for):
|
0
|
|||
|
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G):
|
698,407
|
|||
|
Equals: Balance under scheme(s) not yet
issued/allotted at end of period:
|
1,447,405
|
|||
|
Name of
contact:
|
Victoria
Whyte
|
|
Telephone
number of contact:
|
020
8047 5000
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
26, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|